Detection for effective plasma drug concentration in the field for patients with gastrointestinal stromal tumor with intolerance to 400mg Imatinib

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-15006162

Enrollment

Unknown

Registered

2015-03-30

Start date

2015-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal stromal tumor

Interventions

Experimental group :Imatinib 300mg/d

Control group :Imtinib 400mg/d

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. All tumors were pathologically diagnosed as GIST, and the patients aged from 18 to 80 years old; 2. Patients take imatinib 400mg/d and the ones who decreased imatinib dosage to 300mg/d because of intolerance; 3. Medication duration should not fewer than 28 days for all recruited patients; 4. Patients were informed, and voluntarily signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who refuse to take imatinib; 2. Pregancy or the ones who were alleric to imatinib; 3. Patients who take imatinib irregularly, and medication duration was fewer than 28 days.

Design outcomes

Primary

Measure	Time frame
Plasma concentration of Imatinib;Clinical efficacy (recurrence/metastasis);	—

Secondary

Measure	Time frame
liver/renal function?serum biochemical index;Drug adverse effect;	—

Countries

China

Contacts

Public ContactZhang Bo

hxwcwk@126.com+86 18980601891

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026